Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia

This study has been completed.
Information provided by (Responsible Party):
Cerus Corporation Identifier:
First received: October 26, 2012
Last updated: August 24, 2015
Last verified: June 2015
The clinical study will assess the in-vitro characteristics of red blood cells (RBCs) per the European Union (EU) criteria for leukocyte depleted RBCs in additive solution and evaluate the safety and efficacy of S-303 treated RBCs in a patient population requiring RBC transfusion support for acute anemia.

Condition Intervention Phase
Focus:Use of S303 RBCs in Patients With Acute Anemia
Biological: S-303 Red Blood Cells (RBCs) - Test
Biological: Conventional, untreated red blood cells (RBCs) - Control
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Official Title: A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S 303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia

Resource links provided by NLM:

Further study details as provided by Cerus Corporation:

Primary Outcome Measures:
  • Primary Efficacy Endpoint - mean hemoglobin content [ Time Frame: Day 2 ]
    The mean hemoglobin content per red blood cell (RBC) component compared between the treatment groups

  • Primary Safety Endpoint - Adverse events [ Time Frame: 90 days ]
    The frequency of adverse events (related and unrelated to study RBC components) will be compared between the treatment groups.

Secondary Outcome Measures:
  • Secondary Efficacy Endpoint [ Time Frame: Day 35 ]
    Proportion of RBC components that have adenosine-5'-triphosphate (ATP) levels of greater than 2 μmol/L

  • Secondary Efficacy Endpoint [ Time Frame: Day 35 ]
    Proportion of RBC components that meet the European Union (EU) guideline for hemoglobin content, hematocrit, and hemolysis at the end of storage

  • Secondary Efficacy Endpoint [ Time Frame: Day 35 ]
    Proportion of RBC components that have plasma-free hemoglobin levels corresponding to ≤ 0.8% hemolysis

Other Outcome Measures:
  • Exploratory Endpoint - incidence of renal insufficiency [ Time Frame: Daily on days 0 through 6 ]
    Incidence of renal insufficiency, indicated by serum creatinine level >2 mg/dL WITH at least a 50% increase from pre-operative baseline OR a new requirement for therapy to treat renal insufficiency (dialysis)

  • Exploratory Endpoint - incidence of hepatic insufficiency [ Time Frame: Daily on days 0 through 6 ]
    Incidence of hepatic insufficiency, indicated by total bilirubin that is >2 times the upper limit of normal AND represents at least a 50% increase from the preoperative baseline

  • Exploratory endpoint - Cardiopulmonary function [ Time Frame: Day 7 and 13 ]
    Cardiopulmonary function at the time of first ambulation and at the time of discharge, as measured by a standardized 6 Minute Walk Test (6MWT)

Enrollment: 81
Study Start Date: April 2013
Study Completion Date: October 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: S-303 Treated Red Blood Cells
Patients receive S-303 treated red blood cells (RBCs).
Biological: S-303 Red Blood Cells (RBCs) - Test
Active Comparator: Conventional, untreated Red Blood Cells
Patients receive conventional, untreated red blood cells (RBCs).
Biological: Conventional, untreated red blood cells (RBCs) - Control


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥18 years, of either gender.
  2. Must be willing to use an acceptable form of contraceptive while on study (as approved by the Investigator or designee)
  3. Must be readily available by telephone
  4. Must provide an informed consent for study participation and have signed an ethics committee (EC)-approved informed consent
  5. Must have a negative cross match to S 303 red blood cells (RBCs) at study entry
  6. Must have a blood type of either A+ or O+
  7. Patients must have a likelihood of receiving a transfusion as determined by the Investigator OR a Transfusion Risk Understanding Screening Tool (TRUST) Score of ≥3 at study entry
  8. Must be scheduled to receive one of the following operative procedures:

    • Coronary artery bypass graft only, first procedure
    • Valve repair or replacement only, first procedure
    • A combination of first time Coronary Artery Bypass Graft (CABG) and valve repair or replacement

After consultation with the Medical Monitor, provision can be made to enroll patients who may meet these general criteria but whose surgical procedure is not precisely described in the above categories. Such patients will be classified as "other" with their explicit condition reported with other study data.

Exclusion Criteria:

  1. A positive pregnancy test result
  2. Inability of patient to comply with the protocol in the opinion of the Investigator or attending physician
  3. Breast-feeding of an infant or child
  4. Active autoimmune hemolytic anemia, or a positive Direct Antiglobulin Test (DAT) result
  5. Treatment with any medication that is known to adversely affect red blood cell viability
  6. Emergent or salvage surgical status at the time of surgery defined as follows:

    • Presence of ongoing ischemia including angina at rest despite maximal medical therapy
    • Acute evolving myocardial infarction within 24 hours before surgery
    • Pulmonary edema requiring intubation
    • Presence of shock or hemodynamic instability with or without circulatory support
    • Systolic blood pressure < 80 mm Hg and/or Cardiac Index < 1.8 despite medical intervention (intravenous inotropes or similar pharmacologic agents)
    • Cardiopulmonary resuscitation in the 24 hours prior to surgery or anesthesia induction
    • Requiring an intra-aortic balloon pump or ventricular assist device
  7. Participation in any one of the following types of clinical studies either concurrently or within the previous 28 days: investigational blood products, pharmacologic agents or imaging materials, including dyes, investigational surgical techniques, or devices. Studies of nutrition, psychology, or socioeconomic issues are not grounds for exclusion
  8. Current diagnosis of either chronic or acute renal failure (requiring dialysis) or a serum creatinine greater than or equal to 1.8 mg/dL within 30 days prior to the start of surgery
  9. Current diagnosis of either chronic or acute hepatic insufficiency or a total serum bilirubin greater than or equal to 2.0 mg/dL within 30 days prior to the start of surgery
  10. Pre-existing RBC antibody that may make the provision of compatible study red blood cell (RBC) components difficult
  11. Patients requiring plasma removal or irradiation of the RBC
  12. Patients with prior history of severe allergic transfusion reactions
  13. A positive cross match to S 303 treated RBC

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01716923

Kerckhoff-Klinic GmbH
Bad Nauheim, Hessen, Germany, 61231
Klinikum der J.-W.-G.-Universität Frankfurt
Frankfurt, Germany
Sponsors and Collaborators
Cerus Corporation
Principal Investigator: Arndt H Kiessling, MD Klinikum der J.-W.-G.-Universität Frankfurt
Principal Investigator: Katharina Madlener, Dr Kerckhoff-Klinic GmbH
  More Information

Responsible Party: Cerus Corporation Identifier: NCT01716923     History of Changes
Other Study ID Numbers: CLI 00070
Study First Received: October 26, 2012
Last Updated: August 24, 2015

Additional relevant MeSH terms:
Hematologic Diseases processed this record on May 25, 2017